ArticleImmunoTargets and therapy2026
The Conjugation of Antibodies to Heat Shock Protein 70 Activates Immune Responses Against Tumor Cells.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The heat shock proteins (HSPs) of Methods: Recombinant HSP70, in conjugation with the monoclonal antibodies trastuzumab and bevacizumab, was employed for both in vivo and in vitro treatment of tumor cells. The cytotoxicity of the antibody-HSP70 complex was assessed on the MCF-7, LS174T, and HEK293T cell lines, after characterization of the cells for expression of the targets. The stimulation of complement activation pathways was examined using a complement fixation assay. The in vivo effects of the HSP70- antibodies were evaluated against xenograft LS174T and MCF-7 tumors in mice. The tumor tissues were evaluated through histopathological analysis. Results: The cytotoxic effect of the antibody-HSP70 complex was significantly greater than that of other treatments against the MCF-7 and LS174T cell lines; this effect was confirmed in the presence of human plasma and leukocyte samples. Additionally, activation of the classical complement pathway has been demonstrated using HSP70 antibodies. Treatment of xenograft tumors with the antibody-HSP70 complex significantly reduced both tumor weight and growth rate, as well as decreased the expression of platelet endothelial cell adhesion molecule-1 (PECAM-1). Histopathological analysis, along with the observed therapeutic efficacy, confirmed the safety of this approach. Conclusion: Overall, stimulating the immune system against cancer cells by targeting innate immune responses could enhance the effectiveness of targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.